Advances in targeted therapy for acute myeloid leukaemia
S Kayser, MJ Levis - British journal of haematology, 2018 - Wiley Online Library
In the past few years, research in the underlying pathogenic mechanisms of acute myeloid
leukaemia (AML) has led to remarkable advances in our understanding of the disease …
leukaemia (AML) has led to remarkable advances in our understanding of the disease …
Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric KMT2A-Rearranged AML: Results From the Phase III Children's Oncology …
PURPOSE We investigated the impact of the CD33-targeted agent gemtuzumab ozogamicin
(GO) on survival in pediatric patients with KMT2A-rearranged (KMT2A-r) acute myeloid …
(GO) on survival in pediatric patients with KMT2A-rearranged (KMT2A-r) acute myeloid …
Frontline treatment of acute myeloid leukemia in adults
G Tamamyan, T Kadia, F Ravandi, G Borthakur… - Critical reviews in …, 2017 - Elsevier
Recent years have highlighted significant progress in understanding the underlying genetic
and epigenetic signatures of acute myeloid leukemia (AML). Most importantly, novel …
and epigenetic signatures of acute myeloid leukemia (AML). Most importantly, novel …
Chimeric antigen receptor (CAR) T cell therapy in acute myeloid leukemia (AML)
S Hofmann, ML Schubert, L Wang, B He… - Journal of clinical …, 2019 - mdpi.com
Despite high response rates after initial chemotherapy in patients with acute myeloid
leukemia (AML), relapses occur frequently, resulting in a five-year-survival by< 30% of the …
leukemia (AML), relapses occur frequently, resulting in a five-year-survival by< 30% of the …
CD33 splicing polymorphism determines gemtuzumab ozogamicin response in de novo acute myeloid leukemia: report from randomized phase III Children's …
Purpose Gemtuzumab ozogamicin (GO), a CD33-targeted immunoconjugate, is a re-
emerging therapy for acute myeloid leukemia (AML). CD33 single nucleotide polymorphism …
emerging therapy for acute myeloid leukemia (AML). CD33 single nucleotide polymorphism …
Current approaches in the treatment of relapsed and refractory acute myeloid leukemia
NR Ramos, CC Mo, JE Karp, CS Hourigan - Journal of clinical medicine, 2015 - mdpi.com
The limited sensitivity of the historical treatment response criteria for acute myeloid leukemia
(AML) has resulted in a different paradigm for treatment compared with most other cancers …
(AML) has resulted in a different paradigm for treatment compared with most other cancers …
CD33 expression and its association with gemtuzumab ozogamicin response: results from the randomized phase III Children's Oncology Group Trial AAML0531
JA Pollard, M Loken, RB Gerbing… - Journal of clinical …, 2016 - ascopubs.org
Purpose CD33 is variably expressed on acute myeloid leukemia (AML) blasts and is
targeted by gemtuzumab ozogamicin (GO). GO has shown benefit in both adult and pediatric …
targeted by gemtuzumab ozogamicin (GO). GO has shown benefit in both adult and pediatric …
Factors affecting the pharmacology of antibody–drug conjugates
AT Lucas, LSL Price, AN Schorzman, M Storrie… - Antibodies, 2018 - mdpi.com
Major advances in therapeutic proteins, including antibody–drug conjugates (ADCs), have
created revolutionary drug delivery systems in cancer over the past decade. While these …
created revolutionary drug delivery systems in cancer over the past decade. While these …
Challenges and new frontiers in analytical characterization of antibody-drug conjugates
Antibody-drug conjugates (ADCs) are a growing class of biotherapeutics in which a potent
small molecule is linked to an antibody. ADCs are highly complex and structurally …
small molecule is linked to an antibody. ADCs are highly complex and structurally …